Key facts
- Enodia Therapeutics’s last known valuation is $81.8M (Jan 2026).
- It has raised $24.3M; the latest was Seed Round ($24.3M) in Jan 2026.
- Notable investors include Bpifrance, Elaia Partners, Mission BioCapital, Pfizer Ventures, SambrInvest — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Enodia Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Enodia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Enodia Therapeutics
Operator of a biotechnology research company intended to focus on the discovery and development of treatments for neurodegenerative diseases. The company operates at the translational stage of research, bridging academic science and industrial drug development by advancing therapeutic concepts through preclinical validation and optimization and lead compounds, and prepares candidates for clinical evaluation, enabling clients to transform early scientific findings into viable therapeutic services.
- Sector
- Healthcare
- HQ
- Paris, France
- Founded
- 2025
- Employees
- 1
- Website
- enodiatx.com/
- Ownership
- Privately Held (backing)
Enodia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Enodia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Enodia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.